Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsatuzumab + FOLFOX + Bevacizumab in Metastatic CRC
NCT01399684Phase 2Completed
- Sponsor
- Genentech
- Start
- Nov 2011
- Primary completion
- Feb 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing Parsatuzumab + mFOLFOX-6 + Bevacizumab with Placebo + mFOLFOX-6 + Bevacizumab (2 arms). Primary endpoint: Progression-Free Survival up to 27 months. Started Nov 2011; status: completed.
02
Drugs
parsatuzumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01399684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01399684.